RESUMEN
1 The pharmacokinetics of isoxicam have been compared in 57 volunteers with an average age of 31.3 years and 48 elderly subjects with an average age of 71.9 years. 2 Isoxicam was given in a single daily dose of 200 mg for up to 22 days. Similar plasma concentrations were obtained in the two age groups, average maximum concentrations being 39.7 mg l-1 in those under 65 and 38.1 mg l-1 in the elderly. There were no significant differences in the half-life which averaged 30.4 and 32.1 h respectively. 3 Approximately 9% of all those studied had half-life values in excess of 50 h. The results are consistent with the possibility of genetic polymorphism of isoxicam hydroxylation. 4 It is concluded that isoxicam is suitable for use in once daily dosage and that there are no clinically significant differences in its pharmacokinetics between young and elderly subjects.
Asunto(s)
Envejecimiento/sangre , Antiinflamatorios no Esteroideos/sangre , Piroxicam/análogos & derivados , Adolescente , Adulto , Anciano , Femenino , Semivida , Humanos , Cinética , Masculino , Persona de Mediana Edad , Piroxicam/efectos adversos , Piroxicam/sangreRESUMEN
Twenty-four subjects participated in this placebo-controlled, double-blind study. Eighteen were randomized to receive active enoxacin capsules (400 mg twice daily for 14 days) and the remaining six received placebo therapy. Steady state was reached in four days or less, with an average minimum concentration of 1.25 mg/l and the average concentration achieved 1.5 h after the dose was 3.53 mg/l. Five of 18 (28%) subjects who received active enoxacin and two of six (33%) subjects who received placebo reported adverse events, which were generally mild and of short duration. No rash or pruritus were reported. Haematology, biochemistry and urinalyses revealed no untoward effect.
Asunto(s)
Naftiridinas/administración & dosificación , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Tolerancia a Medicamentos , Enoxacino , Humanos , Cinética , Masculino , Naftiridinas/efectos adversos , Naftiridinas/sangre , Distribución AleatoriaRESUMEN
The main features of the nocturnal EEG of a dwarf with evidence of hypothalamic disease were an increase in slow wave sleep (SWS), a reduction in stage 2 and no alteration in total rapid eye movement. Administration of growth hormone caused a further increase in SWS time.
Asunto(s)
Enanismo Hipofisario/fisiopatología , Fases del Sueño , Niño , Electroencefalografía , Hormona del Crecimiento/farmacología , Humanos , Masculino , Fases del Sueño/efectos de los fármacosRESUMEN
It is suggested that the early-morning growth-hormone release associated with slow-wave sleep is due to inhibition of somatostatin secretion from the hypothalamus. It is also associated with inhibition of gastrointestinal somatostatin, causing a release of gastrin and insulin. Because the levels of glucocorticoid hormones are concurrently low, the insulin effect is unopposed and increases gut motility through augmented vagal tone. This results in an increased delivery of acid to the duodenum. In duodenal-ulcer patients, whose duodenal buffering capacity is reduced because of a relative deficiency of secretin response, this leads to pain.